Cabio Historical Income Statement

688089 Stock

18.09 0.25 1.40%

Historical analysis of Cabio Biotech income statement accounts such as Net Interest Income of 1.7 M, Interest Expense of 856.9 K or Selling General Administrative of 35.2 M can show how well Cabio Biotech Wuhan performed in making a profits. Evaluating Cabio Biotech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cabio Biotech's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Cabio Biotech Wuhan latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cabio Biotech Wuhan is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabio Biotech Wuhan. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Cabio Income Statement Analysis

Cabio Biotech Wuhan Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cabio Biotech shareholders. The income statement also shows Cabio investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Cabio Biotech Income Statement Chart

At present, Cabio Biotech's Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Net Interest Income is expected to grow to about 1.7 M, whereas Selling General Administrative is forecasted to decline to about 35.2 M.

Tax Provision Selling General Administrative Total Revenue Gross Profit

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Total Revenue

Total revenue comprises all receipts Cabio Biotech Wuhan generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Cabio Biotech Wuhan minus its cost of goods sold. It is profit before Cabio Biotech operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most accounts from Cabio Biotech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cabio Biotech Wuhan current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabio Biotech Wuhan. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2022	2023	2024	2025 (projected)
Gross Profit	182.7M	188.2M	216.4M	169.2M
Total Revenue	433.4M	443.8M	510.4M	353.1M

Gross Profit Total Revenue

Cabio Biotech income statement Correlations

	Tax Provision	Net Interest Income	Selling General Administrative	Total Revenue	Gross Profit	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Net Income	Interest Income	Ebitda	Reconciled Depreciation	Minority Interest	Other Operating Expenses	Income Tax Expense
Tax Provision		0.7	0.43	0.68	0.83	0.96	0.96	0.31	0.52	0.56	0.56	0.97	0.95	0.75	0.87	0.12	-0.13	-0.48	-0.09
Net Interest Income	0.7		0.47	0.58	0.67	0.69	0.63	-0.06	0.58	0.5	0.52	0.64	0.63	0.89	0.6	0.04	-0.1	-0.37	-0.13
Selling General Administrative	0.43	0.47		0.86	0.78	0.56	0.27	-0.58	0.86	0.9	0.9	0.3	0.32	0.64	0.0	0.59	0.6	-0.73	-0.79
Total Revenue	0.68	0.58	0.86		0.97	0.84	0.63	-0.26	0.96	0.99	0.99	0.64	0.68	0.68	0.31	0.71	0.51	-0.76	-0.73
Gross Profit	0.83	0.67	0.78	0.97		0.94	0.79	-0.12	0.89	0.92	0.92	0.8	0.83	0.74	0.52	0.6	0.34	-0.73	-0.57
Operating Income	0.96	0.69	0.56	0.84	0.94		0.94	0.16	0.7	0.74	0.74	0.94	0.95	0.73	0.76	0.39	0.08	-0.61	-0.3
Net Income From Continuing Ops	0.96	0.63	0.27	0.63	0.79	0.94		0.37	0.49	0.5	0.5	1.0	1.0	0.64	0.9	0.21	-0.16	-0.42	-0.01
Ebit	0.31	-0.06	-0.58	-0.26	-0.12	0.16	0.37		-0.44	-0.35	-0.37	0.37	0.33	-0.05	0.47	-0.49	-0.65	0.39	0.64
Research Development	0.52	0.58	0.86	0.96	0.89	0.7	0.49	-0.44		0.97	0.97	0.5	0.55	0.66	0.16	0.78	0.58	-0.72	-0.77
Cost Of Revenue	0.56	0.5	0.9	0.99	0.92	0.74	0.5	-0.35	0.97		1.0	0.51	0.55	0.61	0.15	0.76	0.61	-0.75	-0.81
Total Operating Expenses	0.56	0.52	0.9	0.99	0.92	0.74	0.5	-0.37	0.97	1.0		0.51	0.56	0.62	0.16	0.76	0.61	-0.75	-0.81
Income Before Tax	0.97	0.64	0.3	0.64	0.8	0.94	1.0	0.37	0.5	0.51	0.51		1.0	0.66	0.9	0.2	-0.16	-0.43	-0.02
Net Income	0.95	0.63	0.32	0.68	0.83	0.95	1.0	0.33	0.55	0.55	0.56	1.0		0.65	0.88	0.27	-0.11	-0.46	-0.08
Interest Income	0.75	0.89	0.64	0.68	0.74	0.73	0.64	-0.05	0.66	0.61	0.62	0.66	0.65		0.56	0.06	0.01	-0.48	-0.24
Ebitda	0.87	0.6	0.0	0.31	0.52	0.76	0.9	0.47	0.16	0.15	0.16	0.9	0.88	0.56		-0.14	-0.38	-0.27	0.27
Reconciled Depreciation	0.12	0.04	0.59	0.71	0.6	0.39	0.21	-0.49	0.78	0.76	0.76	0.2	0.27	0.06	-0.14		0.74	-0.63	-0.78
Minority Interest	-0.13	-0.1	0.6	0.51	0.34	0.08	-0.16	-0.65	0.58	0.61	0.61	-0.16	-0.11	0.01	-0.38	0.74		-0.71	-0.94
Other Operating Expenses	-0.48	-0.37	-0.73	-0.76	-0.73	-0.61	-0.42	0.39	-0.72	-0.75	-0.75	-0.43	-0.46	-0.48	-0.27	-0.63	-0.71		0.74
Income Tax Expense	-0.09	-0.13	-0.79	-0.73	-0.57	-0.3	-0.01	0.64	-0.77	-0.81	-0.81	-0.02	-0.08	-0.24	0.27	-0.78	-0.94	0.74

Click cells to compare fundamentals

Cabio Biotech Account Relationship Matchups

Cabio Biotech income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Tax Provision	22.8M	20.8M	16.6M	13.6M	15.7M	17.8M
Net Interest Income	3.8M	6.5M	4.0M	1.3M	1.5M	1.7M
Interest Expense	3.6M	351.4K	366.1K	595.5K	684.8K	856.9K
Selling General Administrative	31.5M	31.2M	49.4M	39.0M	44.9M	35.2M
Total Revenue	323.5M	351.1M	433.4M	443.8M	510.4M	353.1M
Gross Profit	178.0M	175.8M	182.7M	188.2M	216.4M	169.2M
Operating Income	114.9M	104.0M	90.1M	92.0M	105.8M	96.8M
Net Income From Continuing Ops	134.9M	131.3M	61.6M	86.4M	99.3M	102.3M
Ebit	93.9M	109.8M	101.7M	67.7M	60.9M	80.5M
Research Development	20.4M	30.9M	32.3M	38.6M	44.4M	25.5M
Cost Of Revenue	145.5M	175.3M	250.8M	255.6M	294.0M	183.9M
Total Operating Expenses	208.6M	247.1M	343.3M	351.8M	404.6M	256.3M
Income Before Tax	157.7M	152.1M	78.1M	100.0M	115.0M	120.1M
Net Income	130.6M	128.6M	64.4M	91.4M	105.1M	102.1M
Interest Income	3.9M	7.0M	5.4M	2.1M	2.4M	3.2M
Ebitda	168.7M	183.7M	176.4M	105.5M	121.3M	162.0M
Reconciled Depreciation	26.0M	24.0M	27.0M	48.3M	55.6M	32.9M
Minority Interest	(4.4M)	(2.7M)	2.8M	5.0M	5.8M	6.0M

Currently Active Assets on Macroaxis

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin
ADA	Cardano
XRP	XRP

Other Information on Investing in Cabio Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cabio Historical Income Statement

About Cabio Income Statement Analysis

Cabio Biotech Income Statement Chart

Tax Provision

Total Revenue

Gross Profit

Cabio Biotech income statement Correlations

Cabio Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cabio Biotech income statement Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in Cabio Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Income Before Tax	+ 1.0	Net Income From Continuing Ops
Net Income	+ 1.0	Net Income From Continuing Ops
Total Operating Expenses	+ 1.0	Cost Of Revenue
Net Income	+ 1.0	Income Before Tax
Cost Of Revenue	+ 0.99	Total Revenue
Total Operating Expenses	+ 0.99	Total Revenue

Income Tax Expense	- 0.94	Minority Interest
Income Tax Expense	- 0.81	Total Operating Expenses
Income Tax Expense	- 0.81	Cost Of Revenue
Income Tax Expense	- 0.79	Selling General Administrative
Income Tax Expense	- 0.78	Reconciled Depreciation
Income Tax Expense	- 0.77	Research Development